- Page 2 and 3:
WORLD HEALTH ORGANIZATION WHO OMS I
- Page 4 and 5:
WORLD CANCER REPORT Editors Bernard
- Page 6 and 7:
CONTENTS Foreword 9 1 The global bu
- Page 8 and 9:
The global burden of cancer Cancer
- Page 10 and 11:
Fig. 1.2 Incidence and mortality of
- Page 12 and 13:
Central and Southern Europe differ
- Page 14 and 15:
Incidence of cancer in South Centra
- Page 16 and 17:
from documentation of disease to a
- Page 18 and 19:
TOBACCO SUMMARY >In addition to lun
- Page 20 and 21:
Fig. 2.3 Smoking by children is inc
- Page 22 and 23:
Cancers positively Sex Standardized
- Page 24 and 25:
PHARMACOLOGICAL APPROACHES TO SMOKI
- Page 26 and 27:
level the dose—response relations
- Page 28 and 29: lipoprotein-associated cholesterol,
- Page 30 and 31: Agent Cancer site/cancer Main indus
- Page 32 and 33: Industry, occupation Cancer site/ca
- Page 34 and 35: to occupational exposures in develo
- Page 36 and 37: Air pollutant WHO Air Quality Guide
- Page 38 and 39: der cancer of the order of 50% is p
- Page 40 and 41: AFLATOXIN B 1 HEPATITIS VIRUS (chro
- Page 42 and 43: Fig. 2.30 Correlation between regio
- Page 44 and 45: MEDICINAL DRUGS SUMMARY > Certain d
- Page 46 and 47: Drug or drug combination Cancer IAR
- Page 48 and 49: Agent or substance Cancer site/canc
- Page 50 and 51: sources of electromagnetic fields [
- Page 52 and 53: CHRONIC INFECTIONS SUMMARY > Infect
- Page 54 and 55: Infection Subclinical Mutagenic fac
- Page 56 and 57: TUMOURS ASSOCIATED WITH HIV/AIDS Ap
- Page 58 and 59: DIET AND NUTRITION SUMMARY > Up to
- Page 60 and 61: Fig. 2.54 The age-adjusted mortalit
- Page 62 and 63: OVERWEIGHT, OBESITY AND PHYSICAL AC
- Page 64 and 65: IMMUNOSUPPRESSION SUMMARY >Persiste
- Page 66 and 67: Fig. 2.64 Cancer following immunosu
- Page 68 and 69: Syndrome Gene Location Cancer site/
- Page 70 and 71: viduals, confirmation of a gene def
- Page 72 and 73: REPRODUCTIVE FACTORS AND HORMONES S
- Page 74 and 75: PHYTO-ESTROGENS AND CANCER PEVENTIO
- Page 76 and 77: Indicator Number of oral contracept
- Page 80 and 81: MULTISTAGE CARCINOGENESIS SUMMARY >
- Page 82 and 83: Peutz-Jeghers polyp other words, no
- Page 84 and 85: Fig. 3.5 Pedunculated hyperplastic
- Page 86 and 87: of the effective biological exposur
- Page 88 and 89: nucleotides may be removed and repl
- Page 90 and 91: SINGLE BASE MISPAIRS INSERTION OR D
- Page 92 and 93: ONCOGENES AND TUMOUR SUPPRESSOR GEN
- Page 94 and 95: Parent heterozygous for RB1 Chromos
- Page 96 and 97: Fig. 3.22 Molecular modelling of pa
- Page 98 and 99: GEOGRAPHIC VARIATION IN MUTATION PA
- Page 100 and 101: THE CELL CYCLE SUMMARY > The contro
- Page 102 and 103: WAF1/CIP1 WAF1/CIP1 Through this me
- Page 104 and 105: several carcinomas (e.g. breast, he
- Page 106 and 107: A Injection into transformed cell B
- Page 108 and 109: increases the level by transiently
- Page 110 and 111: translocation in low grade B cell n
- Page 112 and 113: ane. Bcl-2, Bcl-x L and Bax can for
- Page 114 and 115: worthy is the development of caspas
- Page 116 and 117: Gene Cancer type(s) Mechanism nm23
- Page 118 and 119: Fig. 3.45 Location of metastases at
- Page 120 and 121: TNM CLASSIFICATION OF MALIGNANT TUM
- Page 122 and 123: Prevention and screening The majori
- Page 124 and 125: Europe and North America, but the b
- Page 126 and 127: such as bars and restaurants, who f
- Page 128 and 129:
However the challenge posed is daun
- Page 130 and 131:
REDUCTION OF OCCUPATIONAL AND ENVIR
- Page 132 and 133:
cating that exposure to asbestos ca
- Page 134 and 135:
co-induced disease, including the i
- Page 136 and 137:
REDUCTION OF EXPOSURE TO ULTRAVIOLE
- Page 138 and 139:
dence for the preventive effect of
- Page 140 and 141:
8% = High prevalence 2% - 8% = Inte
- Page 142 and 143:
Fig. 4.20 HBV vaccination of infant
- Page 144 and 145:
Fig. 4.23 Proteins which make up th
- Page 146 and 147:
CHEMOPREVENTION SUMMARY > Chemoprev
- Page 148 and 149:
with non-steroidal anti-inflammator
- Page 150 and 151:
tion trials in humans. We also need
- Page 152 and 153:
100 50 25 10 5 2.5 1 Japan, Miyagi
- Page 154 and 155:
REFERENCES 1. Leitch AM (1999) Brea
- Page 156 and 157:
Abnormal findings in digital rectal
- Page 158 and 159:
SCREENING FOR COLORECTAL CANCER SUM
- Page 160 and 161:
Fig. 4.42 The FOBT test for colorec
- Page 162 and 163:
SCREENING FOR CERVICAL CANCER SUMMA
- Page 164 and 165:
Fig. 4.46 Annual numbers of years o
- Page 166 and 167:
REFERENCES 1. Pontén J, Adami HO,
- Page 168 and 169:
Stage Intervention Control I (4 cm)
- Page 170 and 171:
STOMACH CANCER PREVENTION AND SCREE
- Page 172 and 173:
SCREENING FOR STOMACH CANCER IN JAP
- Page 174 and 175:
REFERENCES 1. Asaka M, Kimura T, Ka
- Page 176 and 177:
LUNG CANCER SUMMARY > Lung cancer i
- Page 178 and 179:
Fig. 5.5 The relative risk of lung
- Page 180 and 181:
Fig. 5.10 Five-year relative surviv
- Page 182 and 183:
BREAST CANCER SUMMARY > Breast canc
- Page 184 and 185:
graphic screening exists, and in fa
- Page 186 and 187:
ATM AND BREAST CANCER Whilst mutati
- Page 188 and 189:
STOMACH CANCER SUMMARY > Cancer of
- Page 190 and 191:
and intestinal metaplasia (Fig. 5.2
- Page 192 and 193:
COLORECTAL CANCER SUMMARY > Cancers
- Page 194 and 195:
Diagnostic criteria for hereditary
- Page 196 and 197:
applies to depressed, flat neoplast
- Page 198 and 199:
tries is high (10-15%) and it can b
- Page 200 and 201:
USA and the percentage is much lowe
- Page 202 and 203:
CANCERS OF THE MALE REPRODUCTIVE TR
- Page 204 and 205:
Prostate Bladder Rectum Fig. 5.47 D
- Page 206 and 207:
Fig. 5.52 Trends in incidence and m
- Page 208 and 209:
Fig. 5.56 Five-year relative surviv
- Page 210 and 211:
Fig. 5.58 A “Healthy Women” gro
- Page 212 and 213:
Fig. 5.63 The global incidence of e
- Page 214 and 215:
have a poorer prognosis for surviva
- Page 216 and 217:
Fig. 5.71 Five-year relative surviv
- Page 218 and 219:
Fig. 5.73 Drinking the scalding bev
- Page 220 and 221:
Factor Alteration Tumour suppressor
- Page 222 and 223:
BLADDER CANCER SUMMARY > Bladder ca
- Page 224 and 225:
Infection with S. haematobium is as
- Page 226 and 227:
HEAD AND NECK CANCER SUMMARY > The
- Page 228 and 229:
structures such as bone, muscles an
- Page 230 and 231:
Chromosome 9p loss 3p, 17p loss sur
- Page 232 and 233:
Fig. 5.98 Non-Hodgkin lymphoma in t
- Page 234 and 235:
Fig. 5.103 Classical Hodgkin diseas
- Page 236 and 237:
LEUKAEMIA SUMMARY > Leukaemia is th
- Page 238 and 239:
A B Fig. 5.111 (A) Bone marrow smea
- Page 240 and 241:
THE MOLECULAR DETECTION OF MINIMAL
- Page 242 and 243:
PANCREATIC CANCER SUMMARY > Pancrea
- Page 244 and 245:
Fig. 5.124 Pancreatic duct showing
- Page 246 and 247:
REFERENCES 1. Jorgensen J, Imrie CW
- Page 248 and 249:
Fig. 5.128 Trends in the incidence
- Page 250 and 251:
Fig. 5.134 Ten-year relative surviv
- Page 252 and 253:
Fig. 5.137 Age-specific incidence o
- Page 254 and 255:
cinoma of greater than 1.5 cm shoul
- Page 256 and 257:
Fig. 5.144 A patient receiving kidn
- Page 258 and 259:
cava involvement reduces five-year
- Page 260 and 261:
Tumour Typical location Age at clin
- Page 262 and 263:
Syndrome Gene Chromo- Nervous syste
- Page 264 and 265:
Cancer management Once cancer is di
- Page 266 and 267:
awareness of cancer has given rise
- Page 268 and 269:
expectation of poor outcome, adjuva
- Page 270 and 271:
RADIOTHERAPY SUMMARY > Radiotherapy
- Page 272 and 273:
individually and onto which marks f
- Page 274 and 275:
MEDICAL ONCOLOGY SUMMARY > The effi
- Page 276 and 277:
6-MERCAPTOPURINE 6-THIOGUANINE Inhi
- Page 278 and 279:
RESISTANCE TO CANCER CHEMOTHERAPY W
- Page 280 and 281:
Immune system Myeloid cells, natura
- Page 282 and 283:
, GENE THERAPY FOR CANCER Technolog
- Page 284 and 285:
tumour cells provides a formidable
- Page 286 and 287:
“burden of care” needed for can
- Page 288 and 289:
CASE EXAMPLES A 90-year-old patient
- Page 290 and 291:
PALLIATIVE CARE SUMMARY > Central t
- Page 292 and 293:
WHO has recommended that in develop
- Page 294 and 295:
Fig. 6.22 The worldwide medical con
- Page 296 and 297:
CANCER CONTROL: A GLOBAL OUTLOOK SU
- Page 298 and 299:
UICC: A UNIQUE ROLE IN GLOBAL CANCE
- Page 300 and 301:
WHO TOBACCO FREE INITIATIVE The Tob
- Page 302 and 303:
CANCER CONTROL IN THE USA: CENTERS
- Page 304 and 305:
CANCER CONTROL IN DEVELOPING COUNTR
- Page 306 and 307:
Regions Number of countries providi
- Page 308 and 309:
, CANCER CONTROL IN A RURAL DISTRIC
- Page 310 and 311:
CANCER CONTROL IN GUINEA, WEST AFRI
- Page 312 and 313:
PERSPECTIVES AND PRIORITIES SUMMARY
- Page 314 and 315:
ETHICS AND CANCER Major ethical iss
- Page 316 and 317:
IMPACT OF THE HUMAN GENOME PROJECT
- Page 318 and 319:
treatment, including palliative car
- Page 320 and 321:
CONTRIBUTORS Dr Alex A. Adjei Mayo
- Page 322 and 323:
Dr Rudolf Kaaks Hormones and Cancer
- Page 324 and 325:
Dr Cecilia Sepúlveda Programme on
- Page 326 and 327:
SOURCES OF FIGURES AND TABLES Figur
- Page 328 and 329:
dence of apoptosis, in Apoptosis: t
- Page 330 and 331:
5.44 IARC/SEER/Osaka Cancer Registr
- Page 332 and 333:
deficient mice. Proc Natl Acad Sci
- Page 334 and 335:
SUBJECT INDEX A Abasic site, 91, 93
- Page 336 and 337:
Comprehensive Cancer Centres, 317 C
- Page 338 and 339:
Infection, 12, 56, 68, 70, 144-149,
- Page 340 and 341:
p27, 105, 106 p53 germline mutation
- Page 342:
Ulcerative colitis-associated color